A study to determine the association between TNF inhibitors and risk of ASCVD in patients with rheumatoid arthritis, which included 2,101 patients with rheumatoid arthritis in a retrospective cohort study, showed a reduced risk of CHD in patients using TNF-α inhibitors and methotrexate (Bili et al., 2014). This evidence concerns the gene TNF and coronary artery disorder.